Cargando…
Targeting Notch1 and proteasome as an effective strategy to suppress T-cell lymphoproliferative neoplasms
The T-cell lymphoproliferative neoplasms (T-LPN) are characterized by a poor clinical outcome. Current therapeutics are mostly non-selective and may induce harmful side effects. It has been reported that NOTCH1 activation mutations frequently associate T-LPN. Because anti-Notch1 based therapies such...
Autores principales: | Yang, Lujun, Zhang, Shuangfeng, George, Suraj Konnath, Teng, Rong, You, Xuefen, Xu, Mengqi, Liu, Hong, Sun, Xiaoping, Amin, Hesham M., Shi, Wenyu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4558128/ https://www.ncbi.nlm.nih.gov/pubmed/25879451 |
Ejemplares similares
-
Dual inhibition of IGF-IR and ALK as an effective strategy to eradicate NPM-ALK(+) T-cell lymphoma
por: George, Bhawana, et al.
Publicado: (2019) -
Correction: Dual inhibition of IGF-IR and ALK as an effective strategy to eradicate NPM-ALK(+) T-cell lymphoma
por: George, Bhawana, et al.
Publicado: (2023) -
Primary pulmonary lymphoproliferative neoplasms
por: Tang, Victoria K, et al.
Publicado: (2018) -
TrkA is a binding partner of NPM‐ALK that promotes the survival of ALK
(+) T‐cell lymphoma
por: Shi, Wenyu, et al.
Publicado: (2017) -
The ALK inhibitor ASP3026 eradicates NPM-ALK(+) T-cell anaplastic large-cell lymphoma in vitro and in a systemic xenograft lymphoma model
por: George, Suraj Konnath, et al.
Publicado: (2014)